Eisai Receives Regulatory Review Outcome For Lecanemab As A Treatment For Early Alzheimer's Disease In Australia
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...
StudyFinds on MSN2h
Gamma stimulation for Alzheimer’s patients: 40-hertz sensory therapy shows tremendous promise
Researchers at MIT have discovered that exposing the brain to light and sound pulses at a specific frequency—40 hertz, or 40 cycles per second—can induce brain rhythms that reduce the hallmark ...
GB News on MSN3h
Alzheimer's breakthrough: Scientists discover why women more at risk of developing dementia than men
Scientists have discovered why women are more at risk of developing dementia than men in a new breakthrough for Alzheimer’s ...
pharmaphorum23h
After FDA nod, Eisai and Biogen file lecanemab in EU
Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in the US ...
Biogen (BIIB) Receives a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...